AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Allogene Therapeutics, Inc. Director's Dealing 2020

Mar 20, 2020

33378_dirs_2020-03-20_7d9cd6c0-7569-481b-b92e-f5ddca2f0d80.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Allogene Therapeutics, Inc. (ALLO)
CIK: 0001737287
Period of Report: 2020-03-18

Reporting Person: SCHMIDT ERIC THOMAS (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-18	Common Stock	A	30800	$0.00	Acquired	78706	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-18	Stock Option (Right to Buy)	$18.22	A	109600	Acquired	2030-03-17	Common Stock (109600)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1227595	Indirect

Footnotes

F1: The securities are held in the name of the Eric Schmidt 2017 Family Irrevocable Trust.

F2: 25% of the shares subject to the stock option shall vest on March 13, 2021, and the remaining shares shall vest in 36 equal monthly installments thereafter.